Study shows positive improvement on combined treatment for wet AMD

Article

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

A phase 2b study1 of OPT-302 (Opthea Ltd.), an anti-vascular endothelial growth factor (VEGF)-C/-D “trap” agent, in combination with ranibizumab (Lucentis, Genentech Inc.) to treat wet age-related macular degeneration (AMD) showed that administering the 2 VEGF inhibits drugs resulted in a larger improvement in visual acuity (VA) after 24 weeks compared with ranibizumab alone.

The rationale behind this treatment was to also inhibit VEGF-C and VEGF-D using OPR-302 in addition to VEGF-A, which ranibizumab, the standard of care for wet AMD, inhibits.

The randomized, double-masked, sham-controlled trial included patients with treatment-naïve neovascular AMD who were treated at 109 sites in Europe, Israel, and the US.

The patients were randomized to 6, every-4-week intravitreal injections of 0.5 mg OPT-302, 2.0 mg OPT-302, or sham plus intravitreal 0.5 mg ranibizumab. The primary outcome was the mean change in Early Treatment Diabetic Retinopathy Study best-corrected VA (BCVA) at 24 weeks. The secondary outcomes were the percentages of patients who gained or lost 15 or more letters of BCVA at 24 weeks compared with baseline and the changes in the central subfield thickness and the intra-retinal and sub-retinal fluid on spectral-domain optical coherence tomography (SD-OCT) images.

OPT-302 results

A total of 366 patients were included from December 1, 2017, to November 30, 2018. Patients were randomized to receive 0.5 mg OPT-302 (n=122), 2.0 mg OPT-302 (n=123), or sham (n=121), respectively.

The investigators reported that the 2.0-mg OPT-302 group had a significant (p=0.01) BCVA gain that was superior to sham (+14.2 ± 11.61 versus +10.8 ± 11.52 letters, respectively). The BCVA gain in the 0.5-mg OPT-302 group did not reach significance (p=0.83) compared with the sham group (+9.44 ± 11.32 letters, respectively). The structural outcomes favored both OPT-302 dosage groups. Adverse events were similar across groups, with 16 (13.3%), 7 (5.6%), and 10 (8.3%) participants in the low-dose, high-dose, and sham groups, respectively, developing at least one serious adverse event. Two unrelated deaths both occurred in the sham arm.

The investigators concluded that “significantly superior vision gain was observed with OPT-302 2.0 mg combination therapy versus the standard of care, with favorable safety.”

Opthea, according to a company press release, is currently conducting two global confirmatory phase 3 studies, ShORe (2 mg OPT-302 + 0.5 mg ranibizumab), and COAST (2 mg OPT-302 + 2 mg aflibercept [Eylea, Regeneron]). The primary endpoint for both studies is the superiority in VA gains at 12 months for the combination therapy compared with standard-of-care monotherapy.

Reference:
1. Jackson TL, Slakter J,Buyse M, et al. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. Published online Feb. 5, 2023; DOI:https://doi.org/10.1016/j.ophtha.2023.02.001

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
© 2025 MJH Life Sciences

All rights reserved.